The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus‐infected people who inject drugs in England
Graham I. Harrison(Nottingham University Hospitals NHS Trust), William L. Irving(University of Nottingham), Martin Wiselka(University Hospitals of Leicester NHS Trust), Magdalena Harris(London School of Hygiene & Tropical Medicine), Archie Christian(The Hepatitis C Trust), Karen Ratcliff(Interaction Design (United Kingdom)), Rosy Reynolds(North Bristol NHS Trust), Charlotte Simpson(Interaction Design (United Kingdom)), Esther Unitt(University Hospitals Coventry and Warwickshire NHS Trust), Penelope Lee(Living Streets), Sandra Oelbaum(Interaction Design (United Kingdom)), Karen F. Murray(Lincoln County Hospital), Brian J. Thomson(Planetary Science Institute), Kerry Trinder(Living Streets), Annette Orton(Living Streets), Paul Richardson(University of Liverpool), Graham R. Foster(Queen Mary University of London), Stuart Smith(The Hepatitis C Trust), Roxanne Gore(Royal Liverpool and Broadgreen University Hospital NHS Trust), Aravamuthan Sreedharan(Lincoln County Hospital), Amanda J. Hughes(Walsall Healthcare NHS Trust), Matthew Hickman(Glasgow Caledonian University), Will Gelson(Cambridge University Hospitals NHS Foundation Trust), Stephen Ryder(Nottingham University Hospitals NHS Trust)
Cited by 44
Related Papers
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
|Hepatology|1998|564
Mental health before and during the COVID-19 pandemic in two longitudinal UK population cohorts
|The British Journal of Psychiatry|2020|533
MAIT cells are activated during human viral infections
|Nature Communications|2016|526
Increase in primary liver cancer in the UK, 1979–94
|The Lancet|1997|506